Why did Gerresheimer reschedule its 2025 results publication?

Gerresheimer rescheduled its 2025 results publication due to an ongoing probe into its revenue recognition and accounting practices.

What did Gerresheimer's internal investigations reveal?

Initial findings from Gerresheimer's investigations indicate that individual employees have violated internal guidelines and International Financial Reporting Standards (IFRS) requirements.

How has the accounting probe affected Gerresheimer's 2025 outlook?

The accounting probe has led Gerresheimer to lower its revenue forecast, reduce its EBITDA margin forecast, and anticipate a high-double-digit percentage decrease in adjusted earnings per share, which may turn negative.

Home / Business and Economy / Revenue Probe Rocks Gerresheimer, 2025 Outlook Cut

Revenue Probe Rocks Gerresheimer, 2025 Outlook Cut

11 Feb

•

Summary

Gerresheimer rescheduled 2025 results due to revenue probe.
Company violated internal guidelines and IFRS requirements.
2025 revenue forecast reduced; earnings per share may turn negative.

Revenue Probe Rocks Gerresheimer, 2025 Outlook Cut

Medical equipment maker Gerresheimer (GXIG.DE) has postponed its 2025 financial results release as it investigates its revenue recognition and accounting practices. This probe follows concerns raised by Germany's financial regulator, BaFin, in September 2024 regarding premature revenue recognition for certain customer contracts.

In addition to rescheduling its results, Gerresheimer is selling its U.S.-based packaging systems business, Centor. The company has engaged a second auditing firm to examine its accounting for 2024 and 2025. Initial findings suggest that some employees have breached internal guidelines and International Financial Reporting Standards (IFRS) requirements.

Consequently, Gerresheimer anticipates a revenue decrease for 2025 at the higher end of its previously forecasted range of minus 4% to minus 2%, or potentially slightly better. The company has also lowered its forecast for earnings before interest, taxes, depreciation, and amortization (EBITDA) margin to between 16.5% and 17.5%, down from 18.5% to 19.0%. Adjusted earnings per share are now projected to decline in the high-double-digit percentage range, possibly becoming negative.